Skip to main content

Organon & Co Value Stock - Dividend - Research Selection

Organon & company

ISIN: US68622V1061 , WKN: A3CPKP

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor

2026-09-16
PhaseV, a leader in machine learning for clinical development, today announced the appointment of Klaus Beck, MD, PhD, PhD, former Chief Medical Officer of Organon, and Avi Kulkarni, PhD, MBA, CEO of InoRx, to its Scientific Advisory Board.

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

2026-09-14
JERSEY CITY, N.J., September 14, 2026--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

Organon: A Merger-Arbitrage Hold With Limited Upside

2026-09-12

The Surprising Pockmarks On Cooper's Earnings That Caused Its Stock To Dive

2026-09-10
Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations.

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

2026-09-02
VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / . ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA.

Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer

2026-09-01
Jeannette Jager, CEO Arletta Pharma Solutions Jeannette Jager van Dijk, appointed Chief Executive Officer of Arletta Pharma Solutions, effective September 1, 2026. www.arlettapharmasolutions.com Global women’s health executive to lead Arletta in its development strategy focused on advancing Lybrido™’s (sildenafil/testosterone) Phase 2 MONARCH study following positive FDA correspondence Effective September 1, 2026Over 30 years of successful global commercial, marketing and product development lea

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

2026-08-27
The first national investigator-led study focused on Canadian women’s experiences of menopause and the menopausal transition is now inviting participants, in partnership with GreenShield and supported by a charitable grant from OrganonTORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC) and the Partnership for Women’s Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Informa

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

2026-08-24
Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

IHF: Healthcare Dashboard For August

2026-08-16
Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.

Orogen Royalties Announces Results of the 2026 Annual General Meeting

2026-08-13
VANCOUVER, BC / ACCESS Newswire / August 13, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the voting results for its Annual General Meeting (the "Meeting") of shareholders held August 13, ...